Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000914965
Ethics application status
Approved
Date submitted
25/06/2020
Date registered
16/09/2020
Date last updated
28/01/2024
Date data sharing statement initially provided
16/09/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
The C*STEROID Trial: Corticosteroids before planned caesarean section from 35+0 to 39+6 weeks of pregnancy.
Scientific title
The C*STEROID Trial. Antenatal corticosteroids prior to planned caesarean section delivery from 35+0 to 39+6 weeks gestation; a randomised controlled trial assessing the effects on neonatal respiratory morbidity and glycaemic control.
Secondary ID [1] 301624 0
None
Universal Trial Number (UTN)
U1111-1254-2168
Trial acronym
The C*STEROID Trial
Linked study record
ACTRN12618002028280. This record is the C*STEROID Feasibility Study a pilot study of this study with participant data contributing to The C*STEROID Trial.

Health condition
Health condition(s) or problem(s) studied:
Caesarean section delivery 318015 0
Respiratory distress syndrome 318016 0
Transient tachypnoea of the newborn 318017 0
Neonatal hypoglycaemia 318018 0
Condition category
Condition code
Respiratory 316042 316042 0 0
Other respiratory disorders / diseases
Reproductive Health and Childbirth 316043 316043 0 0
Complications of newborn

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Two doses of 11.4mg betamethasone by intramuscular injection into the thigh, arm or buttock, 24 hours apart given within seven days of planned caesarean section. Adherence will be assessed by review of the drug accountability log and/or medication chart.
Intervention code [1] 317926 0
Prevention
Comparator / control treatment
0.9% sodium chloride (NaCl) in a visually matching syringe.
Control group
Placebo

Outcomes
Primary outcome [1] 324254 0
Incidence of respiratory distress requiring >60 minutes of respiratory support (neonatal outcome). Includes mechanical and non-invasive ventilation where sum of both is >60 minutes (e.g. intermittent positive pressure via endotracheal tube, nasal continuous positive airway pressure, Hi- or Lo-flow oxygen/air mix or increased ambient oxygen delivered into an incubator). >60 minutes has been selected to eliminate short-term support which may be subject to variation by clinician. Data will be collected by review of hospital/neonatal unit records.
Timepoint [1] 324254 0
Primary hospital discharge
Primary outcome [2] 324255 0
Incidence of neonatal hypoglycaemia (blood glucose level <2.6 mmol/L) prior to primary hospital discharge. Data will be collected by review of hospital records and/or glucose oxidase test results.
Timepoint [2] 324255 0
Primary hospital discharge
Secondary outcome [1] 384177 0
Neonatal Unit (NNU) admission assessed by review of hospital/neonatal unit medical records.
Timepoint [1] 384177 0
Primary hospital discharge
Secondary outcome [2] 384178 0
Duration of Neonatal Unit (NNU) stay assessed by review of hospital/neonatal unit medical records.
Timepoint [2] 384178 0
Primary hospital discharge
Secondary outcome [3] 384179 0
Duration of neonatal hospital stay (to primary hospital discharge) assessed by review of hospital medical records.
Timepoint [3] 384179 0
Primary hospital discharge
Secondary outcome [4] 384180 0
Duration of respiratory support (sum of mechanical and non-invasive) (neonatal outcome). Data will be collected from hospital medical records.
Timepoint [4] 384180 0
Primary hospital discharge
Secondary outcome [5] 384181 0
A composite outcome of severe respiratory distress defined as any mechanical ventilation and/or need for surfactant therapy (neonatal outcome). Data will be collected from hospital medical records.
Timepoint [5] 384181 0
Primary hospital discharge
Secondary outcome [6] 384182 0
Severe hypoglycaemia defined as blood glucose level <1.2 mmol/L (neonatal outcome). Data will be collected by review of hospital records and/or glucose oxidase test results.
Timepoint [6] 384182 0
Primary hospital discharge
Secondary outcome [7] 384183 0
Early onset infection and/or late onset infection as defined by the Australian and New Zealand Neonatal Network (ANZNN). Data will be collected from hospital medical records.
Timepoint [7] 384183 0
Primary hospital discharge
Secondary outcome [8] 384184 0
Maternal self-reported adverse effects of injections including gastrointestinal upset; insomnia; pain, bruising or infection at injection site. Data will be collected from hospital records and study-specific surveys.
Timepoint [8] 384184 0
Primary hospital discharge
Secondary outcome [9] 384185 0
Maternal perinatal infectious morbidity requiring postpartum antibiotic therapy. Data will be collected from a study-specific survey and if required additional details will be obtained from the hospital records, prescription records, study-specific surveys and GP/LMC records.
Timepoint [9] 384185 0
Six weeks postpartum
Secondary outcome [10] 384186 0
Duration of maternal postnatal stay (to primary hospital discharge). Data will be collected from hospital medical records.
Timepoint [10] 384186 0
Primary hospital discharge
Secondary outcome [11] 384187 0
Breastfeeding (exclusive and full) at six weeks postpartum. This will be collected from a study-specific survey.
Timepoint [11] 384187 0
Six weeks postpartum
Secondary outcome [12] 384188 0
Maternal wellbeing and psychological status measured at six weeks postpartum.This will be collected from a study-specific survey and the Edinburgh Postnatal Depression Scale.
Timepoint [12] 384188 0
Six weeks postpartum
Secondary outcome [13] 384884 0
Moderate respiratory distress defined as respiratory support (sum of mechanical and non-invasive) for >24 hours (neonatal outcome). Data will be collected from hospital medical records.
Timepoint [13] 384884 0
Primary hospital discharge
Secondary outcome [14] 406397 0
To undertake a cost-effectiveness analysis of the intervention. This will include the cost of the intervention and hospital care for the birth admission to discharge home, and health service utilisation data from Medicare. Cost-effectiveness will be reported as cost per life year gained, cost per infant with respiratory distress prevented, and cost per QALY.
Timepoint [14] 406397 0
Cost of the intervention: to primary hospital discharge. Health service utilisation: until 2 years of age.

Eligibility
Key inclusion criteria
1. Women for whom caesarean section is planned pre-labour at 35+0 to 39+6 weeks gestation.
2. >24 hours and <7 days before planned birth.
3. Singleton or twin pregnancy with a live fetus.
Minimum age
No limit
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Diabetes: pre-existing or gestational.
2. Major fetal abnormality.
3. Prior corticosteroid use in this pregnancy (intramuscular corticosteroid use for fetal lung maturity).
4. Prior enrolment in the C*STEROID Feasibility Study or C*STEROID Trial, in a previous pregnancy.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
28/09/2020
Actual
7/10/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
2548
Accrual to date
762
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 26104 0
Royal Hospital for Women - Randwick
Recruitment hospital [2] 26105 0
The Royal Women's Hospital - Parkville
Recruitment hospital [3] 26106 0
St George Hospital - Kogarah
Recruitment hospital [4] 26107 0
Joan Kirner Women’s and Children’s Hospital - St Albans
Recruitment hospital [5] 26108 0
Mercy Hospital for Women - Heidelberg
Recruitment hospital [6] 26109 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [7] 26110 0
Box Hill Hospital - Box Hill
Recruitment hospital [8] 26111 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [9] 26112 0
Womens and Childrens Hospital - North Adelaide
Recruitment hospital [10] 26113 0
Ballarat Health Services (Base Hospital) - Ballarat Central
Recruitment hospital [11] 26114 0
Liverpool Hospital - Liverpool
Recruitment hospital [12] 26115 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [13] 26116 0
The Northern Hospital - Epping
Recruitment hospital [14] 26117 0
Townsville University Hospital - Douglas
Recruitment hospital [15] 26118 0
Ipswich Hospital - Ipswich
Recruitment hospital [16] 26119 0
Epworth Freemasons (Clarendon Street) - East Melbourne
Recruitment hospital [17] 26120 0
Djerriwarrh Health Service - Bacchus Marsh - Bacchus Marsh
Recruitment postcode(s) [1] 41960 0
2031 - Randwick
Recruitment postcode(s) [2] 41961 0
3052 - Parkville
Recruitment postcode(s) [3] 41962 0
2217 - Kogarah
Recruitment postcode(s) [4] 41963 0
3021 - St Albans
Recruitment postcode(s) [5] 41964 0
3084 - Heidelberg
Recruitment postcode(s) [6] 41965 0
2065 - St Leonards
Recruitment postcode(s) [7] 41966 0
3128 - Box Hill
Recruitment postcode(s) [8] 41967 0
4029 - Herston
Recruitment postcode(s) [9] 41968 0
5006 - North Adelaide
Recruitment postcode(s) [10] 41969 0
3350 - Ballarat Central
Recruitment postcode(s) [11] 41970 0
2170 - Liverpool
Recruitment postcode(s) [12] 41971 0
3168 - Clayton
Recruitment postcode(s) [13] 41972 0
3076 - Epping
Recruitment postcode(s) [14] 41973 0
4814 - Douglas
Recruitment postcode(s) [15] 41974 0
4305 - Ipswich
Recruitment postcode(s) [16] 41975 0
3002 - East Melbourne
Recruitment postcode(s) [17] 41976 0
3340 - Bacchus Marsh
Recruitment outside Australia
Country [1] 22694 0
New Zealand
State/province [1] 22694 0
Auckland, Waikato, Wellington, Christchurch, Whangarei

Funding & Sponsors
Funding source category [1] 306055 0
Government body
Name [1] 306055 0
Health Research Council of New Zealand (HRC)
Country [1] 306055 0
New Zealand
Funding source category [2] 306056 0
Charities/Societies/Foundations
Name [2] 306056 0
Cure Kids
Country [2] 306056 0
New Zealand
Funding source category [3] 306057 0
Charities/Societies/Foundations
Name [3] 306057 0
Lottery Health Research
Country [3] 306057 0
New Zealand
Funding source category [4] 306058 0
Charities/Societies/Foundations
Name [4] 306058 0
The Hugo Charitable Trust
Country [4] 306058 0
New Zealand
Funding source category [5] 310802 0
Government body
Name [5] 310802 0
National Health and Medical Research Council Medical Research Future Fund (MRFF) International Clinical Trial Collaborations Program (NHMRC MRFF ICTC)
Country [5] 310802 0
Australia
Primary sponsor type
University
Name
The University of Auckland
Address
Liggins Institute
The University of Auckland
85 Park Road
Private Bag 92019
Grafton
Auckland 1142
New Zealand
Country
New Zealand
Secondary sponsor category [1] 306519 0
University
Name [1] 306519 0
The University of Melbourne
Address [1] 306519 0
Grattan Street, Parkville, Victoria, 3010
Country [1] 306519 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 306281 0
Northern B Health and Disability Ethics Committee
Ethics committee address [1] 306281 0
Ethics committee country [1] 306281 0
New Zealand
Date submitted for ethics approval [1] 306281 0
21/07/2020
Approval date [1] 306281 0
28/09/2020
Ethics approval number [1] 306281 0
20/NTB/166
Ethics committee name [2] 310370 0
Melbourne Health Human Research Ethics Committee
Ethics committee address [2] 310370 0
Ethics committee country [2] 310370 0
Australia
Date submitted for ethics approval [2] 310370 0
Approval date [2] 310370 0
05/05/2021
Ethics approval number [2] 310370 0
HREC/73793/MH-2021

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 103354 0
Prof Katie Groom
Address 103354 0
Professor of Maternal and Perinatal Health, Hugo Charitable Trust Research Fellow, Maternal Fetal Medicine Subspecialist, The University of Auckland, 85 Park Road, Grafton Private Bag 92019, Auckland 1142
Country 103354 0
New Zealand
Phone 103354 0
+64 9 3737599
Fax 103354 0
Email 103354 0
[email protected]
Contact person for public queries
Name 103355 0
Katie Groom
Address 103355 0
Professor of Maternal and Perinatal Health, Hugo Charitable Trust Research Fellow, Maternal Fetal Medicine Subspecialist, The University of Auckland, 85 Park Road, Grafton Private Bag 92019, Auckland 1142
Country 103355 0
New Zealand
Phone 103355 0
+64 9 3737599
Fax 103355 0
Email 103355 0
[email protected]
Contact person for scientific queries
Name 103356 0
Katie Groom
Address 103356 0
Professor of Maternal and Perinatal Health, Hugo Charitable Trust Research Fellow, Maternal Fetal Medicine Subspecialist, The University of Auckland, 85 Park Road, Grafton Private Bag 92019, Auckland 1142
Country 103356 0
New Zealand
Phone 103356 0
+64 9 3737599
Fax 103356 0
Email 103356 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified individual participant data underlying published results.
When will data be available (start and end dates)?
Immediately following publication which is anticipated to occur after 2024, no end date determined.
Available to whom?
The de-identified data that support the findings of this study will be made available upon request to researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by an independent review committee identified for this purpose.
Available for what types of analyses?
Any purpose which has received approval from an independent review committee, and is approved by the Trial Steering Committee.
How or where can data be obtained?
Access subject to approvals by Trial Steering Committee. Contact via Katie Groom: [email protected]


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
8339Study protocol  [email protected]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.